Pharmacogenomic Result in a Patient Facing Clopidogrel After Stenting
A 61-year-old man undergoes drug-eluting stent placement after an acute coronary syndrome. His cardiologist orders CYP2C19 genotyping before starting clopidogrel. The result is CYP2C19 *2/*17 (one no-function allele and one increased-function allele), which the laboratory reports as 'intermediate metabolizer' per its diplotype-to-phenotype table. The patient is also on omeprazole for GERD. The cardiologist asks whether to switch to ticagrelor and whether the phenotype call is reliable.
1. Evaluate the phenotype assignment and the clinical implication for clopidogrel.
Read the worked answer
CYP2C19 *2/*17 combines one no-function allele with one increased-function allele. Under the standard CPIC diplotype-to-phenotype system, this is classified as an intermediate metabolizer because the decreased-function effect of *2 is not fully offset by *17 in the activity score model (activity score typically 1.0). The clinical implication is reduced formation of the active clopidogrel metabolite and a higher risk of adverse cardiovascular events on clopidogrel after ACS/PCI. CPIC guidance recommends an alternative P2Y12 inhibitor (e.g., ticagrelor or prasugrel, absent contraindications) for intermediate and poor metabolizers in this setting. The phenotype call is defensible but should be reported with the diplotype and activity score, since some laboratories use different phenotype labels for *17-containing genotypes.
2. What drug–gene and drug–drug interactions modify the interpretation, and how would you counsel?
Read the worked answer
Omeprazole is a CYP2C19 inhibitor and can further reduce activation of clopidogrel, compounding the reduced-function effect of the *2 allele. The combination of an intermediate-metabolizer genotype plus a CYP2C19-inhibiting PPI increases the likelihood of inadequate platelet inhibition. Counseling: (1) the genotype is lifelong and should be documented; (2) if clopidogrel is retained, avoid strong CYP2C19 inhibitors such as omeprazole/esomeprazole and consider pantoprazole, which has less CYP2C19 inhibition; (3) the preferred approach in ACS/PCI is an alternative P2Y12 inhibitor per CPIC, weighing bleeding risk; (4) the *17 allele does not confer protection here and should not be read as 'fast metabolizer' overall. The decision is a clinical risk-benefit judgment, not a deterministic genotype-driven mandate.
3. What quality-assurance elements should accompany this pharmacogenomic report?
Read the worked answer
QA elements include: (1) a validated genotyping assay with documented accuracy for *2, *3, *17 and other tested alleles, including confirmation of rare or ambiguous diplotypes by an orthogonal method; (2) a validated, version-controlled diplotype-to-phenotype table aligned with current CPIC guidance, with the activity score reported; (3) clear reporting of the alleles tested and the residual risk of untested variants (e.g., rare decreased-function alleles not on the panel); (4) interpretive language that states the recommendation is guidance, not a mandate, and notes interacting medications; (5) participation in proficiency testing and periodic review of the phenotype table as guidelines update; (6) documentation of informed consent and result communication, since pharmacogenomic results have implications for relatives. The report should avoid a single 'intermediate metabolizer' label without the underlying diplotype and activity score.